BOH-2C-B


BOH-2C-B, or BOHB, also known as 4-bromo-2,5-dimethoxy-β-hydroxyphenethylamine or as β-hydroxy-2C-B, is a psychedelic drug of the phenethylamine, 2C, and BOx families. It is the β-hydroxy derivative of 2C-B. The drug has been encountered as a novel designer drug.

Use and effects

BOH-2C-B was not included or mentioned in Alexander Shulgin's book PiHKAL. Subsequently, Daniel Trachsel listed BOHB's dose as 30mg or more orally in his book Phenethylamine: von der Struktur zur Funktion.

Pharmacology

Pharmacodynamics

BOH-2C-B acts as a serotonin 5-HT2A receptor agonist.

Chemistry

BOH-2C-B is a substituted phenethylamine. It features methoxy substituents at the 2- and 5-position of the ring, as well as a bromine at the 4-position. A hydroxy group is present at the beta position from the functional amine group connected to the alpha carbon, giving rise to its name.

Analogues

Analogues of BOH-2C-B include 2C-B, BOB, βk-2C-B, β-methyl-2C-B, BOHD, and BOD, among others.

History

BOH-2C-B was first described in a 2004 study by Richard Glennon and colleagues on β-oxygenated 5-HT2A serotonin receptor agonists, although it is not mentioned by name. It was encountered as a novel designer drug in 2019. However, it is said to have been on the market since 2015.

Society and culture

Legal status

BOH-2C-B is a controlled substance in the following countries:
  • Canada: BOH-2C-B is a controlled substance under phenethylamine blanket-ban language.
  • Germany: BOH-2C-B is controlled under the New Psychoactive Substances Act as of November 26, 2016. Possession is illegal but not penalized.
  • Netherlands:: BOH-2C-B is not specifically scheduled in the NL but may be considered a ring-derived analogue of 2-phenethylamine which would make it illegal under updates made to the Dutch Opium Act in February 2024.
  • United Kingdom: BOH-2C-B is illegal to produce, supply or import under the Psychoactive Substance Act as of May 26, 2016.
  • United States: BOH-2C-B is unscheduled in the U.S., but may be considered an analogue of 2C-B under the Federal Analogue Act, and thus a Schedule I drug.